# A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood

> **NCT05934942** · PHASE1 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 29 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Yasmin®
- **DRUG:** BI 1358894

## Key facts

- **NCT ID:** NCT05934942
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-09-08
- **Primary completion:** 2024-02-08
- **Final completion:** 2024-02-08
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** Company decision
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05934942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05934942, "A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05934942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*